Specialty Pharmaceutical Company Deploys TransPerfect Technology to Streamline TMF Operations Specialty Pharmaceutical Company Deploys TransPerfect Technology to Streamline TMF Operations
Continue reading here:
Gedeon Richter Selects Trial Interactive for Clinical Trial Management
Revisionen af selskabets årsrapport for 2023 er ikke afsluttet. Årsrapporten offentliggøres på onsdag den 27. marts 2024 i henhold til selskabets finanskalender.
Read more:
Foreløbige tal for 2023 og finansielle forventninger til 2024
OXURION announces its presence at the Paris SmallCapevent on March 28, 2024.
Read more:
OXURION announces its presence at the Paris SmallCap event on March 28, 2024.
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET.
See more here:
BioCryst to Present at Upcoming Investor Conferences
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET
See the original post:
Praxis Precision Medicines to Host PRAX-628 Program Update
ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the Company and for other general corporate and operating purposes.
See more here:
OpGen Announces Acquisition of Preferred Stock by David Lazar
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients.
Excerpt from:
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost?effective diagnosis of complex syndromes placed worldwide by the end of 2023 QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost?effective diagnosis of complex syndromes placed worldwide by the end of 2023
Read more from the original source:
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter and full year ended December 31, 2023.
Read more here:
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results